期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

急性髓系白血病靶向治疗新进展 被引量：4

New advances on targeted therapy for acute myeloid leukemia
暂未订购
导出
摘要 急性髓系白血病(acute myeloid leukemia,AML)是成人最常见的急性白血病。针对AML,虽然近年来在完全缓解(complete remission,CR)率与无病生存(disease free survival,DFS)率上都有明显提高,但还有将近一半患者不能获得长期生存,复发和难治仍然是影响AML疗效的瓶颈。过去的十几年来,AML的靶向药物不断推陈出新,但真正被证实能改善患者预后的药物非常有限。
作者 蒋灵旭 罗颖婉 佟红艳 JIANG Ling-xu;LUO Ying-wan;TONG Hong-yan(MDS Center, Department of Hematology,the First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou 310003,China)
机构地区 浙江大学医学院附属第一医院血液科MDS中心
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2018年第12期1198-1202,共5页 Chinese Journal of Practical Internal Medicine
基金 国家自然科学基金面上项目(81470290).
关键词 急性髓系白血病 靶向治疗 靶向免疫治疗 acute myeloid leukemia targeted therapy targeted immunotherapy
分类号 R551.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献3

二级参考文献80

  • 1王妍,韩燕星,蒋建东.刺孢霉素族抗生素的研究进展[J].中国新药杂志,2007,16(17):1341-1345. 被引量：4
  • 2Robillard N, Wuilleme S, Lode L, Magrangeas F, Minvielle S, Avetloiseau H. CD33 is expressed on plasma cells of a significant number of rnyeloma patients, and may represent a therapeutic target. Leukemia 2005; 19: 2021-2.
  • 3Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007; 7: 255-66.
  • 4Pollard JA, Ho PA, Bemstein ID, Walter RB, Meshinchi S, Alon- zo TA, et al. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood 2012; 119(12): 3705-11.
  • 5Lorenz U. SHP-1 and SHP-2 in T cells: Two phosphatases func- tioning at many levels. Rev Immunol 2009; 228(1): 342-59.
  • 6Walter RB, Raden BW, Zeng R, Hausermann P, Bernstein ID, Cooper JA. ITIM-dependent endocytosis of CD33-related Si- glecs: Role of intracellular domain, tyrosine phospborylation, and the tyrosine phosphatases, Shpl and Shp2. J Leuk Bio 2008; 83(1): 200-1.
  • 7Balaian L, Ball ED. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signal- ing pathways. Exp Hematol 2005; 33: 199-211.
  • 8Ravandi F, Ester EH, Appelbaum FR, Lo-Coco F, Schiller CA, Larson RA, et al. Gemtuzumab Ozogamicin: Time to Resurrect? J Clin Oncol 2012; 30(32): 3921-3.
  • 9Larson RA, Sievers EL, Stadtmaner EA, Lowenberg B, Estery EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first recurreneel. Cancer 2005; 104(7): 1442-52.
  • 10Pagano L, Fianchi L, Caira M, Rutella S and Leone G. The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene 2007; 26: 3679-90.

共引文献80

同被引文献51

引证文献4

二级引证文献18

中国实用内科杂志
2018年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部